Challenge the Global Marketwith the Power of Creation

Challenge the Global Marketwith the Power of Creation

From Japan to the worldFrom Japan to the world

Manufactured by

1-6-21 Sogawa, Toyama, JapanPhone: +81-3-5649-7163　Fax: +81-3-6861-5550http://www.nichiiko.co.jp/english

Message from thepresident and CEO

Nichi-Iko’s Sales

Generic Market Share in Japan

©2014 IMS. Calculated based on JPM(Jul 2013-June 2014 monthly basis) (HP/GP/PH). Reprinted with permission.

Medical Institution Coverage in Japan

Nichi-Iko is No.1Generic Maker in JapanAiming to become Global Top 10 Generic maker

Mission StatementWe, Nichi-Iko, make good efforts by ourselves to be sustainable for providing value-added, high quality generic products which meet various requirements from patients, doctors, pharmacists, wholesalers and pharmaceutical companies in the global market as one of the most respected, well established generic companies in the world.

Nichi-IkoA CorporationB CorporationC CorporationD CorporationOthers

10.7%

9.4%

5.6%

4.4%

3.9%66%

Total: 8.2 billion USD

000

200

400

600

800

1,000

1,200

1,400

1,600(million USD)

01 02 03 04 05 06 07 08 09 10 11 12 13 14 1615

Sales

Year

With continuous growth since 2000,Nichi-iko achieved record sales ofover 1 billion USD in 2014.

Pharmacies

Clinics

Hospitals

ALL

InstitutionTotal Number of

Institutionsin Japan

−

62.4%

16.4%

21.2%

100.0% 134,623

8,421

65,776

54,464

−

97.9%

64.4%

96.2%

8,604

102,098

56,639

SalesComposition

Number ofClients

CoveredRatio

2014

●1USD = 100 JPY●Year 2012 shows only 4 months sales performance　(December 2011- March 2012) due to fiscal term change.●Year 2015 and 2016 are estimated sales.

In the same year, we made a strategic move for global expansion through our local subsidiaries established in Thailand and U.S. We have been keen to build a strategic alliance with partners in other countries.

Generic pharmaceuticals are expected to play an even bigger role in the world with the aim of medical cost containment as well as relieving financial burden on patients. As the times have changed, not only low-price, but also high-quality and trusted generic products have been valued and needed among any other products.

Nichi-Iko Group will continuously strive to supply high-quality and trusted generic products which are “made in Japan” . We strongly expect to become a company that is trusted and chosen by customers through grasping needs of customers all over the world appropriately and fulfilling them swiftly. We never cease to “Challenge the Global Market” with a spirit of challenge.

Nichi- Iko Group is committed to i ts act iv i t ies aiming to become “one of the TOP 10 generic pharmaceut i ca l compan ies in the wor ld ” in accordance with our motto, “Challenge the Global Market with the Power of Creation”.

We have cont inued to be posi t ioned as No.1 generic maker in Japan and successfully achieved a sales goal of 1 bi l l ion USD in 2014 through establishing the largest production capabilities of 11 billion tablets and 100 million injectables among other domestic generic makers.

1 2Nichi-Iko Pharmaceutical Co.,Ltd. Nichi-Iko Pharmaceutical Co.,Ltd.

With annual sales of over 1 billion USD, Nichi-Iko has built a strong presence in the Japanese market and is No.1 generic pharmaceutical company in Japan. It offers a full line-up of generic drugs covering more than 900 products.

Nichi-Iko’s Premium QualityProducts born from State-of-the -Art Production Facilities

Main Products

Various kinds of machines inclean quality control room.

Blister packing machine withCCD camera to

detect defective products.

Granulation machine.

Visual inspection of lyophilized products todetect foreign particles.

Monitoring system todetect defective products.

Tablets printed with the name of“Nichi-Iko” in Japanese using laser printer.

Automatic packing machine.

GMP standardsICH Q10 Pharmaceutical Quality SystemOne machine in One room to avoid contamination“11 billion tablets and 100 million injections” - Japan’s largest production capability

Osteoporosis agent

Long-acting calcium antagonist

HMG-CoA reductase inhibitor

Moisturizing agent

Selective β blocker

Antiplatelet agent

Disturbance of consciousness agent

Alzheimer's dementia agent

Fosfomycin-type antibiotic agent

Sulfonylurea-type oral hypoglycemic agent

Proton pump inhibitor

Prostaglandin E1

Long-acting angiotensin receptor blocker/Diuretic agentAngiotensin II receptor blocker

Calcium antagonist

Proton pump inhibitor

Gastritis and stomach ulcers agent

Joint function improving agent

Chronic renal failure agent

Angiotensin l receptor blocker

Sleep inducing drug

Alendronate Tablets 5mg/35mg

Amlodipine Tablets 2.5mg/5mg/10mg, OD Tablets2.5mg/5mg/10mg

Atorvastatin Tablets 5mg/10mg/20mg

Besoften® Spray 0.3%, Gel 0.3%, Cream 0.3%,Oil-based Cream 0.3%, Lotion 0.3%

Bisoprolol Fumarate Tablets 0.625mg/2.5mg/5mg

Cilostazol Tablets 50mg/100mg, Ciloslet Oral Jelly50mg/100mg

Citicoline Injection 100mg/2mL,250mg/2mL,500mg/2mL,500mg/10mL,1000mg/4mL

Donepezil Hydrochloride Tablets 3mg/5mg/10mg,OD Tablets 3mg/5mg/10mg, Fine Granules 0.5%

Fosfomycin Capsules 250mg/500mg, Dry Syrup 40%Fosfomycin IV Injection 0.5g/1g/2g

Glimepiride Tablets 0.5mg/1mg/3mg

Lansoprazole Capsules 15mg/30mg, OD Tablets15mg/30mg

Limaprost Alfadex Tablets 5μg

Losarhyd® LD Tablets (Losartan potassium:50mg,Hydrochlorothiazide:12.5mg)Losartan PotassiumTablets 25mg/50mg/100mg

Manidipine Hydrochloride Tablets 5mg/10mg/20mg

Rabeprazole Na Tablets 10mg/20mg

Rebamipide Tablets 100mg, Granules 20%

Sodium Hyaluronate IA Injection 25mg

Spherical Adsorption Charcoal Capsules 286mg,Fine Granules Divided Pack 2g

Valsartan Tablets 20mg/40mg/80mg/160mg

Zolpidem Tartrate Tablets 5mg/10mg

Alendronate sodium hydrate

Amlodipine besilate

Atorvastatin calsium hydrate

Heparinoid

Bisoprolol fumarate

Cilostazol

Citicoline

Donepezil hydrochloride

Fosfomycin calsium hydrate

Fosfomycin sodium

Glimepiride

Lansoprazole

Limaprost alfadex

Losartan potassium,HydrochlorothiazideLosartan potassium

Manidipine hydrochloride

Rabeprazole sodium

Rebamipide

Purified sodium hyaluronate

Spherical adsorption charcoal

Valsartan

Zolpidem tartrate

MSD

Sumitomo DainipponPharma, Pfizer

Astellas, Pfizer

Maruho

Mitsubishi Tanabe Pharma

Otsuka

Takeda

Eisai, Pfizer

Meiji Seika Pharma

Sanofi

Takeda

Ono, Sumitomo DainipponPharma

MSD

MSD

Takeda

Eisai

Otsuka

Chugai, Kaken, Seikagaku

Daiichi-Sankyo, MitsubishiTanabe Pharma

Novartis

Astellas

Therapeutic Classification Nichi-Iko Product Active Ingredient Originator in Japan

3 4Nichi-Iko Pharmaceutical Co.,Ltd. Nichi-Iko Pharmaceutical Co.,Ltd.

Partners : Sanofi

Partners : Aprogen,Binex

Partners : Stason,KCST

Partners :Hanoi

Pharma

Partners : DKSH

Partners :DKLL,Biolab,

Biopharm

Partners : DKSH

Subsidiary:

Subsidiary:

Nichi-Iko Distribution Center

East Japan Distribution Center

Yamagata PlantAntiseptic liquids

West Japan Distribution Center

Toyama Plant 2Oral drug products (powder, granules)

Saitama PlantValue-added(preparations, external preparations, eyedrops)

Yakuhan Pharmaceutical Co., Ltd.Antiseptic liquids

Aichi PlantInjection products (ampoules, liophylization)

Nichi-Iko Pharma Tech Shizuoka PlantOral drug products (tablets, injections)

R&D siteHoneycomb building(Toyama)

Toyama Plant 1Oral drug products (tablets, capsules)

From Japan’s No.1 to be Global Top 10 Generic Maker　9 Branch officesSapporo, Sendai, Kanto, Tokyo 1st,Tokyo 2nd, Tokai-Hokuriku, Osaka,Hiroshima, Fukuoka

2 Overseas subsidiariesThailand : USA :

　2 Head QuartersTokyo HQToyama HQ

Development, Production,Distribution Network and Global Alliances

5 6Nichi-Iko Pharmaceutical Co.,Ltd. Nichi-Iko Pharmaceutical Co.,Ltd.